Anti-Müllerian hormone (AMH), secreted by granulosa cells of preantral and small antral follicles, regulates folliculogenesis by inhibiting primordial follicle recruitment and modulating FSH sensitivity. Clinically established as a biomarker of ovarian reserve, AMH is now emerging as a potential therapeutic target across women’s health.

AMH modulation offers unique opportunities in fertility preservation, contraception, and reproductive longevity. Sustained AMH activity may protect the ovarian reserve from chemotherapy or age-related depletion. Pharmacologic AMH could provide a novel contraceptive by temporarily suppressing follicular activation while maintaining endocrine cyclicity. In menopause delay strategies, AMH analogs may extend reproductive lifespan and mitigate health risks of early ovarian failure.

In IVF, AMH-based therapies could improve controlled ovarian stimulation (COS) by creating a more uniform and optimally sized follicular cohort, reducing premature activation, and enhancing both oocyte yield and quality. Recombinant AMH analogs, engineered for stability and high receptor affinity, have shown in preclinical models to improve oocyte yield in both normal and poor responding models.

Ongoing development focuses on defining optimal dosing, timing, and patient selection. Early clinical trials will need to confirm safety, reversibility, and impact on reproductive outcomes. If validated, AMH therapeutics could represent a new class of mechanism-driven interventions—transforming AMH from a static biomarker into an active tool for managing fertility, preserving ovarian reserve, and extending reproductive healthspan.

Learn more about Granata Bio’s innovative pipeline here.